A retrospective longitudinal analysis of ambulatory care data with a median follow-up of 3.5 years showed that twice-daily exenatide use with or without insulin was associated with significantly fewer cardiovascular events than insulin treatment [101]
Xiang GD, Pu JH, Snu HL, and Zhao LS
Obesity is a chronic condition, and maintaining weight loss often requires continued structure, follow-up, nutrition planning, strength training, and sometimes continued medication
Introduction Starting a weight loss journey often brings a mix of excitement and a few unexpected challenges
Compound 59 was the most potent XO inhibitor in vitro, with an IC 50 value of 1.37 M, being 117.81 times more active than geniposide and 9.14 times more active than the drug allopurinol (Figure 18)
What are the benefits and risks of using retatrutide (a GLP1, GIP, and glucagon receptor agonist) for weight loss in adults with obesity?